🚀 AstraZeneca Pharma India Jumps Over 5% on Key Drug Approval!

As of 13 April 2026,

surged over 5% after receiving approval from CDSCO to import, sell, and distribute Acalabrutinib (100 mg). The drug, combined with venetoclax (± obinutuzumab), targets untreated CLL and SLL patients—marking a major oncology milestone. Despite opening with a 3.3% gap-down, the stock staged a sharp intraday recovery, rallying 10.85% from the day’s low to hit its highest level (8895) since 2 March 2026. In April alone, the company’s market cap has risen over 12%. However, on a year-to-date basis, the stock remains over 3% lower in CY2026. 📊 Strong momentum backed by regulatory progress. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.